🔎︎
An FDA advisory committee voted unanimously on June 18, 2026, to support Moderna’s mRNA-based seasonal influenza vaccine, mFlusiva (mRNA-1010), a step toward potential clearance of the first messenger RNA flu vaccine in the United States. BioPharma Dive reported that the Vaccines and Related Biological Products Advisory Committee voted 9-0 that the vaccine’s benefits outweigh its risks in adults aged 50 to 64 and separately supported its use in adults aged 65 and older. Moderna is seeking standard approval for adults aged 50 to 64 and accelerated approval for adults aged 65 and older. The FDA decision is expected by August 5.
For managed care organizations, the clinical and access considerations differ. The pivotal trial, published in the New England Journal of Medicine, found that the vaccine reduced the risk of influenza illness by approximately 27% compared with a standard-dose flu vaccine in adults aged 50 and older. The reported relative benefit, along with the speed associated with mRNA manufacturing, may draw attention from health plans. A platform that can be adjusted to better match circulating seasonal strains could be relevant for a vaccine category in which effectiveness varies by season.
Timing may affect near-term uptake. Industry analysts have noted that Moderna missed the 2026 contracting window for the upcoming flu season. As a result, meaningful uptake and revenue may be limited before the second half of 2027, even if approval occurs on the expected timeline. Formulary placement, contracting, and immunization recommendations would follow approval, which currently falls after many purchasing decisions for the season have been made.
Coverage considerations may also differ for adults aged 65 and older. The application for this age group relies largely on immune response data measured against a standard-dose comparator, rather than on the high-dose flu vaccines that current guidance favors for older adults. A confirmatory trial of up to 800,000 participants across two seasons is planned. Health plans evaluating placement for older members may wait for additional data and final recommendations before making coverage decisions.
For payers, the near-term implication is monitoring and preparation rather than immediate contracting activity. If approved, the vaccine would add a new option to the flu vaccine market, but it is not expected to substantially affect the current season.
